ZENAS BIOPHARMA INC (ZBIO)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ZBIO
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ZBIO | Director | 39 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| SYRE | Director | 39 | [] | [] | 2026 |
| APGE | Independent Director | 39 | [] | [] | 2026 |
| VRDN | Independent Chairman of the Board | 39 | [] | [] | 2026 |
| JBIO | Founding Partner, Fairmount Funds Management LLC; Director | 39 | [] | ["Compensation Committee"] | 2026 |
| DNTH | Independent Director | 37 | [] | [] | 2024 |
Biography sourced from the proxy statement filing.
Tomas Kiselak , has served as a member of our board of directors since September 2020. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, which he co-founded in April 2016. In addition to Zenas, Mr. Kiselak has served as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) since October 2020. He also serves on the boards of Apogee Therapeutics, Inc. (Nasdaq: APGE), Jade Biosciences, Inc. (Nasdaq: JBIO), and Spyre Therapeutics, Inc. (Nasdaq: SYRE), as well as several private companies. Mr. Kiselak previously serve